Show Summary Details
Page of

Principles of drug use in palliative care 

Principles of drug use in palliative care
Chapter:
Principles of drug use in palliative care
Author(s):

Max Watson

, Rachel Campbell

, Nandini Vallath

, Stephen Ward

, and Jo Wells

DOI:
10.1093/med/9780198745655.003.0005
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 22 August 2019

This chapter includes a formulary of the drugs most commonly used in the palliative care setting as well as advice surrounding common pharmacological challenges. These include drug interactions, prescribing in patients with co-morbidities, managing toxicity, the use of syringe drivers, and the impact of medications on driving. It provides a useful overview of current pharmacological practice in the UK in the context of end-of-life care and the need to consider both deprescribing as well as escalation of treatment when appropriate. By law in the UK, a medication must be given a MA (formally, a product license) by the Medicines and Healthcare Products Regulatory Agency (MHRA). The MA specifies the indication, dose, route and patient populations for which the drug can be marketed. Drugs can be used legally in clinical situations that fall outside the remit of the MA, referred to as ‘off-label’ (e.g. a different indication, dose, route, or method of administration than that specified in the MA). Off-label use of drugs in palliative care is routine, with the responsibility for prescribing under such circumstances lying with the prescriber. The prescriber must be fully informed about the actions and uses of the medicinal product and should provide information on the benefits and risks of off-license prescribing to the patient (or their proxy) to facilitate an informed decision regarding treatment options.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.